Therapy-induced APOBEC3A drives evolution of persistent cancer cells-Reference-Cited by-同舟云学术

Therapy-induced APOBEC3A drives evolution of persistent cancer cells

Published:2023-07-05 Issue:7973 Volume:620 Page:393-401
ISSN:0028-0836
Container-title:Nature
language:en
Short-container-title:Nature

Author:

Isozaki Hideko^ORCID,Sakhtemani Ramin^ORCID,Abbasi Ammal,Nikpour Naveed,Stanzione Marcello,Oh Sunwoo^ORCID,Langenbucher Adam,Monroe Susanna^ORCID,Su Wenjia,Cabanos Heidie Frisco,Siddiqui Faria M.,Phan Nicole,Jalili Pégah,Timonina Daria,Bilton Samantha,Gomez-Caraballo Maria,Archibald Hannah L.,Nangia Varuna^ORCID,Dionne Kristin,Riley Amanda^ORCID,Lawlor Matthew,Banwait Mandeep Kaur,Cobb Rosemary G.,Zou Lee^ORCID,Dyson Nicholas J.,Ott Christopher J.^ORCID,Benes Cyril^ORCID,Getz Gad,Chan Chang S.^ORCID,Shaw Alice T.^ORCID,Gainor Justin F.,Lin Jessica J.^ORCID,Sequist Lecia V.^ORCID,Piotrowska Zofia,Yeap Beow Y.,Engelman Jeffrey A.,Lee Jake June-Koo^ORCID,Maruvka Yosef E.,Buisson Rémi^ORCID,Lawrence Michael S.^ORCID,Hata Aaron N.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

https://www.nature.com/articles/s41586-023-06303-1.pdf

Reference64 articles.

1. Kobayashi, S. et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 352, 786–792 (2005).

2. Engelman, J. A. et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316, 1039–1043 (2007).

3. Sequist, L. V. et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci. Transl Med. 3, 75ra26 (2011).

4. Gainor, J. F. et al. Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer. Cancer Discov. 6, 1118–1133 (2016).

5. Salter, J. D., Bennett, R. P. & Smith, H. C. The APOBEC protein family: united by structure, divergent in function. Trends Biochem. Sci. 41, 578–594 (2016).

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Next generation APOBEC3 inhibitors: Optimally designed for potency and nuclease stability;2024-09-06

2. Cancer drug-tolerant persister cells: from biological questions to clinical opportunities;Nature Reviews Cancer;2024-09-02

3. Regulation, functional impact, and therapeutic targeting of APOBEC3A in cancer;DNA Repair;2024-09

4. Cancer plasticity in therapy resistance: Mechanisms and novel strategies;Drug Resistance Updates;2024-09

5. Mutational signatures and their association with cancer survival and gene expression in multiple cancer types;International Journal of Cancer;2024-08-28